银屑病关节炎一线csDMARD单药保留率:甲氨蝶呤优于柳氮磺吡啶
这项回顾性队列研究纳入187例未用过DMARD的成人银屑病关节炎患者,首次以csDMARD单药治疗,主要用甲氨蝶呤(n=163)或柳氮磺吡啶(n=21)。甲氨蝶呤中位药物保留时间34.5个月,显著高于柳氮磺吡啶的12.0个月(P=0.016)。多变量Cox回归显示使用甲氨蝶呤和年龄较大与保留率增加相关。
要点
- 甲氨蝶呤中位保留34.5个月,柳氮磺吡啶为12.0个月,差异有统计学意义。
- 治疗失败主因是无效(52%)和副作用(28%)。
- 甲氨蝶呤失败后更常换用生物制剂。
核心结论
- 在未用过DMARD的银屑病关节炎患者中,甲氨蝶呤作为一线csDMARD单药的药物保留优于柳氮磺吡啶。
研究设计与样本
- 回顾性队列研究,纳入187例未用过DMARD的成人银屑病关节炎患者,首次csDMARD单药治疗,主要用甲氨蝶呤(n=163)或柳氮磺吡啶(n=21)。
主要发现
- 总体中位药物保留时间为31.8个月(四分位距9.04-110)。
- 甲氨蝶呤中位保留34.5个月(四分位距9.60-123),柳氮磺吡啶中位12.0个月(四分位距4.80-55.7),P=0.016(log-rank检验)。
- 多变量Cox回归中,使用甲氨蝶呤和年龄较大与保留率增加相关。
- 治疗失败主因为无效(52%)和副作用(28%)。
- 甲氨蝶呤治疗失败后更常后续使用生物制剂(P<0.05)。
关键数值与推荐
- 主要结局为csDMARD失败时间,即停用csDMARD或加用其他DMARD。
临床怎么用
- 在每日临床实践中,甲氨蝶呤可作为未用过DMARD的银屑病关节炎患者一线csDMARD单药的优先选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Conventional synthetic DMARDs (csDMARDs) are the first-line treatment for PsA, but there is conflicting data regarding their efficacy and scarce reports describing the duration of use (drug retention) of csDMARD in this population. Their position in treatment recommendations is a matter of growing debate due to the availability of alternative treatment options with higher levels of evidence. We aimed to study drug retention and predictors for drug retention among PsA patients receiving first-line csDMARD monotherapy. METHODS: Retrospective cohort study in DMARD-naïve adult PsA patients in whom a first csDMARD was prescribed as monotherapy primarily to treat PsA-related symptoms. The main outcome was time to failure of the csDMARD (i.e. stopping the csDMARD or adding another DMARD). RESULTS: A total of 187 patients were included, who were mainly prescribed MTX (n = 163) or SSZ (n = 21). The pooled median drug retention time was 31.8 months (interquartile range 9.04-110). Drug retention was significantly higher in MTX (median 34.5 months; interquartile range 9.60-123) as compared with SSZ-treated patients (median 12.0 months; interquartile range 4.80- 55.7) (P =0.016, log-rank test). In multivariable Cox regression, the use of MTX and older age were associated with increased retention. The main reasons for treatment failure were inefficacy (52%) and side effects (28%). Upon failure, MTX treated patients were more commonly, subsequently treated with a biologic DMARD compared with SSZ (P < 0.05). CONCLUSION: MTX outperforms SSZ as a first-line csDMARD in DMARD-naïve PsA patients with respect to monotherapy drug retention in daily clinical practice.
引用
- Jacobs ME, Pouw JN, Welsing P, et al. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine. Rheumatology (Oxford). 2021. PMID: 32797218. doi:10.1093/rheumatology/keaa399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。